Oncology - Bolstering Oral Agent Reporting Related to Distress

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Individuals on oral chemotherapy (OC) often face many challenges requiring adequate informational support, monitoring, and management. This pilot randomized control trial (RCT) aims to assess the feasibility, acceptability, and preliminary effects of a comprehensive OC intervention on medication adherence self-efficacy, medication adherence, and symptom distress.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03858712` - EHR-embedded OCDT in Breast or GI Cancer	N/A

NCT number	NCT04984850
Study type	Interventional
Source	McGill University
Contact
Status	Completed
Phase	N/A
Start date	January 7, 2022
Completion date	January 30, 2024

Oncology - Bolstering Oral Agent Reporting Related to Distress — ON-BOARD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms